1月29日上午，国家主席习近平在北京人民大会堂会见来华进行正式访问的英国首相斯塔默。新华社 记者 李响 摄 1月29日上午，国家主席习近平在北京人民大会堂会见来华进行正式访问的英国首相斯塔默。 双方同意中英要发展长期稳定的全面战略伙伴关系。 习近平指出，当前国际局势变乱交织，中英作为联合国安理会常任理事国和世界主要经济体， 无论是维护世界和平稳定，还是促进两国经济民生，都需要加强对话和合作。中方愿同英方秉 持大历史观，超越分歧、相互尊重，把中英合作"大有可为"的潜力转化成"大有作为"的实绩， 为中英关系与合作开新局，既造福两国人民，也惠及世界。 习近平强调，互信是国与国关系行稳致远的基础。中国始终坚持走和平发展道路，从未主动挑 起过一场战争，从未侵占过别国一寸土地，中国无论怎样发展壮大都不会对其他国家构成威 胁。中国的文化传统是"以和为贵"，追求的是"和而不同"。中英经贸合作的本质是互利共赢。 今年是中国"十五五"开局之年，双方要拓展教育、医疗、金融、服务业互利合作，开展人工智 能、生物科学、新能源和低碳技术等领域联合研究和产业转化，实现共同发展繁荣。希望英方 为中国企业提供公平、公正、非歧视的营商环境。中英 ...

Core Insights - The bilateral trade between Europe and China has reached approximately 800 billion euros, a significant increase from 50 years ago when trade volumes were low [1] Group 1: Trade Relations - The trade relationship between Europe and China has evolved significantly over the past five decades, highlighting the importance of data in understanding this growth [1] - The current trade volume of around 800 billion euros indicates a robust economic partnership that has developed over time [1] Group 2: Future Opportunities - Future challenges and cooperation opportunities are emphasized as critical areas of focus, particularly in fields like biosciences and quantum mechanics [1] - Collaboration between scientists and students, as well as exchanges among the general public and business communities, are deemed essential for fostering deeper ties [1]

Group 1 - The flu season in China may arrive earlier this year, with a higher number of infections expected due to a different circulating strain, primarily H3N2, compared to last year's H1N1 strain, leading to lower immunity in the population [1] - The treatment options for influenza include symptomatic treatment, antiviral therapy, and traditional Chinese medicine, with antiviral drugs such as neuraminidase inhibitors, RNA polymerase inhibitors, and hemagglutinin inhibitors being highlighted [1] - There is a recommendation to pay attention to the market for antiviral drugs, respiratory disease medications, and flu vaccines [1] Group 2 - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in vaccine research, production, biotechnology, and life sciences tools and services to reflect the overall performance of the bioproducts and life sciences sector [1] - The index components focus on innovative drug development and disease prevention, showcasing the technological development trends and investment value in the bioscience industry [1]

Core Viewpoint - The "AI Augmented Biology" conference aims to explore the integration of artificial intelligence with biological sciences, facilitating groundbreaking discoveries and advancements in the field [4]. Group 1: Conference Details - The conference is organized by Nanjing University, the Chinese Biophysics Society, and several prestigious journals including Nature and Nature Biotechnology [2]. - It will take place from October 22 to 24, 2025, in Nanjing, with both online and offline participation [2]. - The agenda includes sessions on the interface of AI and biomedicine, AI in the multi-omics era, and decoding the language of molecules [5]. Group 2: Topics of Discussion - Key topics will include multimodal data mining, protein engineering, molecular and cellular engineering, and the application of large language models to understand complex biological systems and diseases [4]. - The conference will feature important milestones and breakthroughs in AI technology as applied to biological research [4]. Group 3: Editorial Participation - Editors from the Nature series journals will be present, providing opportunities for attendees to engage with them [5]. - Notable editors include Cheng Qian from Nature Communications and Angela Eggleston from Nature [5][6]. Group 4: Accommodation Information - Recommended hotels include Nanjing Zijin Mountain Villa with room rates starting at 450 RMB for a double room [14]. - Alternative accommodation is available at Jiangsu Conference Center, approximately 20 minutes from the venue, with rates starting at 380 RMB [14].

Summary of the Conference Call for 康龙化成 (Crown Bioscience) Q1 2025 Company Overview - 康龙化成 reported a revenue of 30.96 billion CNY in Q1 2025, representing a year-on-year growth of 15.4% [2][3] - The company maintains its revenue growth guidance for 2025 at 10% to 15% and expects to continue generating positive free cash flow [2][9] Key Financial Performance - The adjusted net profit for Q1 2025 was 3.49 billion CNY, a year-on-year increase of 3.1%, while the net profit attributable to shareholders was 3.06 billion CNY, up 32.5% [3][4] - The laboratory services segment generated 18.57 billion CNY, with a gross margin of 45.5%, up 1.4 percentage points [2][5] - The small molecule CDMO services segment reported revenue of 6.93 billion CNY, with a gross margin of 30.4%, an increase of 2.5 percentage points [2][5] - Clinical services revenue was 4.47 billion CNY, with a gross margin of 11.8%, up 2.5 percentage points [2][5] - The revenue from large molecule and cell & gene therapy services was 99 million CNY, showing a year-on-year growth of 7.9% [2][5] Revenue Breakdown by Region and Client Type - Revenue from Chinese laboratories and factories grew by 15.7%, accounting for 88% of total revenue; overseas revenue increased by 18.3%, making up 12% [2][6] - North American client revenue rose by 16.8%, representing 65% of total revenue; European client revenue increased by 26%, accounting for 18% [2][6] Order Growth and Market Trends - New orders maintained a double-digit growth of over 10% in Q1 2025, continuing the trend from the previous year [2][7] - The CMC business is focused on early clinical stages, with expectations for several large projects to advance into later stages, which will enhance CMC revenue and overall performance [4][23] Strategic Initiatives and Future Outlook - The company is investing in advanced technologies in the biosciences field, including 3D cell culture and organ-on-a-chip models, to stay at the forefront of industry developments [4][12] - The company anticipates that the adjusted net profit growth will accelerate from Q2 2025 onwards as operational efficiencies improve [3][4] - The overall market for laboratory services and biosciences is expected to continue its recovery, with double-digit growth anticipated in both sectors [9][20] Challenges and Considerations - The company faces challenges related to increased operational costs and depreciation due to new capacity coming online in 2024 [4][3] - The impact of geopolitical factors, such as tariffs and the IRA Act, on client R&D and production needs is being monitored, but the company remains optimistic about its growth trajectory [14][19] Conclusion - 康龙化成's Q1 2025 performance reflects strong growth across its segments, with a positive outlook for the remainder of the year, driven by strategic investments and a robust order pipeline [29]